kallikrein related peptidase 11Genealiases: IEKD · PRSS20 · TLSP
Q-omics provides the consensus-scored KLK11 profile across patient tissues and cancer cell-line models. KLK11 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KLK11 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, KLK11 RNA expression shows 12,330 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where KLK11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLK11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLK11 survival associations across molecular data types. KLK11 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLK11 RNA expression–survival associations across cancer types. High KLK11 expression shows unfavorable associations in KIRC, KIRP and PAAD, but favorable associations in MESO, LUAD and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KLK11 RNA expression.
This table summarizes KLK11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KLK11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLK11 shows lower tumor expression in HNSC, LUAD, BRCA and KIRC and higher tumor expression in THCA and COAD. The HNSC box plot shows higher KLK11 RNA expression in normal versus tumor tissue (log2 FC = −1.906, t-test p < 0.001).
This table shows molecular features associated with KLK11 in patient tissues and cancer cell lines. In patient samples, KLK11 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KLK11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LUNG_SCLC.
